Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1361910 | Bioorganic & Medicinal Chemistry Letters | 2011 | 4 Pages |
Abstract
A weak, UDP-competitive antagonist of the pyrimidinergic receptor P2RY14 with a naphthoic acid core was identified through high-throughput screening. Optimization provided compounds with improved potency but poor pharmacokinetics. Acylglucuronidation was determined to be the major route of metabolism. Increasing the electron-withdrawing nature of the substituents markedly reduced glucuronidation and improved the pharmacokinetic profile. Additional optimization led to the identification of compound 38 which is an 8 nM UDP-competitive antagonist of P2Y14 with a good pharmacokinetic profile.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jacques Yves Gauthier, Michel Belley, Denis Deschênes, Jean-François Fournier, Sébastien Gagné, Yves Gareau, Martine Hamel, Martin Hénault, Huda Hyjazie, Stacia Kargman, Geneviève Lavallée, Jean-François Levesque, Lianhai Li, Yaël Mamane, Joseph Mancini,